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Background. Non-selective cyclooxygenase (COX) inhibitors or non-steroidal anti-
in¯ammatory drugs (NSAIDs) are frequently omitted for perioperative pain relief because of
potential side-effects. COX-2-selective inhibitors may have a more favourable side-effect
pro®le. This study tested the hypothesis that the COX-2-selective inhibitor rofecoxib has less
in¯uence on platelet function than the NSAID diclofenac in gynaecological surgery. In addition,
analgesic ef®cacy and side-effects of the two drugs were compared.
Methods. In this single-centre, prospective, double-blind, active controlled study, women
undergoing vaginal hysterectomy (n=25) or breast surgery (n=25) under general anaesthesia
received preoperatively 50 mg of rofecoxib p.o. followed 8 and 16 h later by two doses of pla-
cebo or three doses of diclofenac 50 mg p.o. at the same time points. We assessed arachidonic
acid-stimulated platelet aggregation before and 4 h after the ®rst dose of study medication,
estimated intraoperative blood loss, and haemoglobin loss until the ®rst morning after surgery.
Analgesic ef®cacy, use of rescue analgesics, and side-effects were also recorded.
Results. In the rofecoxib group, stimulated platelet aggregation was disturbed less (P=0.02),
and estimated intraoperative blood loss (P=0.01) and the decrease in haemoglobin were lower
(P=0.01). At similar pain ratings, the use of anti-emetic drugs was less in the rofecoxib group
(P=0.03).
Conclusion. Besides having a smaller effect on platelet aggregation, one oral dose of rofecoxib
50 mg given before surgery provided postoperative analgesia similar to that given by three
doses of diclofenac 50 mg and was associated with less use of anti-emetics and less surgical
blood loss in gynaecological surgery compared with diclofenac.
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Perioperative use of non-steroidal anti-in¯ammatory drugs
(NSAIDs) reduces postoperative pain1 and opioid consump-
tion2 but may be associated with side-effects.3±5
Cyclooxygenase-2 (COX-2)-selective inhibitors represent
an alternative treatment with a more favourable side-effect
pro®le, including less effect on platelet function6 and the
gastrointestinal tract.7 The perioperative use of COX-2
inhibitors, however, is not yet established.
We therefore performed this double-blind, active con-
trolled study to assess the effect of rofecoxib 50 mg
compared with three oral doses of diclofenac 50 mg on
platelet aggregation and other parameters of blood coagu-
lation in gynaecological surgery. In addition, we compared
ef®cacy, intraoperative blood loss, loss of haemoglobin,
consumption of analgesics, renal function, and other side-
effects.
Patients and methods
The study was approved by the Ethical Committee of the
University Hospital Zurich and conducted in accordance
with the principles of the Declaration of Helsinki. All
patients enrolled in the study gave written informed consent.
This single-centre, double-blinded, active controlled
study was conducted on 50 female patients (29±74 yr)
who underwent surgery in the Department of Gynaecology,
University Hospital of Zurich, Switzerland. No placebo
group was included as exclusion of patients from standard
analgesic treatment was deemed ethically inappropriate.
Two sets of patients were studied in parallel: 25 patients
scheduled for vaginal hysterectomy and 25 patients under-
going surgery for suspected breast cancer. The hysterec-
tomy group was included to allow measurement of
creatinine clearance, as only these patients are routinely
instrumented with a bladder catheter. Patients were
excluded if they had a history of gastrointestinal bleeding
or gastric, duodenal or oesophageal ulceration; Crohns'
disease, ulcerative colitis or liver disease; aspartate
transaminase or alanine transaminase concentrations
above twice upper normal values; hepatic porphyria;
serum creatinine above 105 mmol litre±1; history of bron-
chial asthma, intracranial bleeding within the last 6 months,
pregnancy or breastfeeding; history of bleeding disorders,
prolonged prothrombin time, platelet count below 150 000
mm±3, anticoagulant therapy, received acetylsalicylic acid
within the last 7 days, NSAID therapy within 48 h, opioid
treatment within 72 h before surgery or immunosuppres-
sants, including corticosteroids, anti-epileptics or nephro-
toxic drugs; or hypersensitivity to one of the study drugs or
anaesthetics.
Patients in both surgical subsets were block-randomized
into the diclofenac or rofecoxib group using a computer-
generated table. The study medication was prepared by the
hospital pharmacy. Placebo capsules were ®lled with lactose
and were indistinguishable from the active treatment. All
persons involved in the conduct of the study and the patients
were blinded regarding the group assignment. After oral
premedication with midazolam 3.75 or 7.5 mg, blood
specimens were taken for coagulation tests when the patient
arrived in the operating theatre.
In the diclofenac group subjects received 50 mg
diclofenac sodium (Voltarenâ; Novartis, Bern,
Switzerland) orally just before anaesthesia induction,
followed by 50 mg 8 and 16 h later. In the rofecoxib
group, rofecoxib 50 mg (Vioxxâ; MSD, Glattbrugg,
Switzerland) was administered orally just before anaesthe-
sia induction, followed by placebo 8 and 16 h later. A
standardized general anaesthetic technique was used for
induction (propofol 1.5±2.5 mg kg±1, fentanyl 2 mg kg±1,
rocuronium bromide 0.6 mg kg±1) and maintenance
(propofol 4±10 mg kg±1 h±1, one dose of fentanyl 2 mg
kg±1 before skin incision). The use of propofol, remifentanil
and nicomorphine was left to the discretion of the
anaesthetist and the doses given were recorded.
(Nicomorphine is an opioid with the same potency as
morphine.) Before the end of surgery, tropisetron 2 mg was
administered to all patients to prevent postoperative nausea
and vomiting (PONV). In the recovery room patients
received nicomorphine i.v. according to their needs.
Before the patients were transferred to the ward, patient-
controlled analgesia (PCA) was started (nicomorphine,
initial setting 1 mg bolus dose, 5 min lockout time, no basal
infusion rate). PCA settings were changed according to the
needs of the patient.
Patients were assessed at four speci®c time points: 1 and
4 h after emergence, and 8 h and 24 h after the ®rst dose of
the study medication. Pain was evaluated using the visual
analog scale (VAS, 0 mm=no pain, 100 mm=worst pain
imaginable). PONV was rated using a four-item scale (1=no
nausea, 2=nausea, 3=vomiting, 4=intractable vomiting).
The administered doses of the rescue anti-emetics (tropise-
tron 2 mg i.v. and dihydrobenzperidol 1.25 mg i.v.) were
recorded. The following variables and side-effects were also
recorded: heart rate, systolic and diastolic blood pressures,
use of nicomorphine or rescue analgesics, other side-effects
regarding the gastrointestinal tract, sedation and headache.
Other events, e.g. increased bleeding, need for further
surgery and haematemesis, were recorded throughout the
24 h observation period.
Pain scores were assessed by patients at 8 and 24 h using a
®ve-item categorical verbal rating scale (VRS) (1=poor,
2=moderate, 3=good, 4=very good, 5=excellent).8
Similarly, patients were asked to rate their satisfaction
with respect to PONV on a ®ve-item categorical VRS at 8
and 24 h (1=poor, 2=moderate, 3=good, 4=very good,
5=excellent).
The surgeon estimated intraoperative blood loss in
millilitres, and the activity of the coagulation system
using a ®ve-item scale (1=no coagulation, 2=poor, 3=mod-
erate, 4=good, 5=increased coagulation). According to
standard practice, all patients received low molecular
weight heparin dalteparine sodium 2500 IU s.c. at 6 p.m.
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daily, starting the evening before surgery. Citrated blood for
the coagulation studies was sampled just before the
administration of the trial drug and again 4 h later.
Platelet function was assessed by classical platelet aggre-
gometry according to Born, using an automated platelet
aggregation coagulation tracer (APACT; Labor, Hamburg,
Germany). All measurements were performed in platelet-
rich plasma using arachidonic acid (2 mmol litre±1),
collagen (5 mmol litre±1) and ADP (5 mmol litre±1) as
aggregation inducers. To additionally determine the degree
of inhibition of arachidonic acid metabolism of the platelets,
the malondialdehyde (MDA) content of the platelets was
determined as described previously.9 MDA is produced by
the degradation of prostaglandin H2, which is a product of
the COX-1-mediated degradation of arachidonic acid.
Inhibition of COX-1 results in decreased concentrations of
MDA.
The Thrombelastograph Coagulation Analyzer (CTEG
3000; Haemoscope, Morton Grove, IL, USA) with 1%
celite activation was used, and the blood was recalci®ed
and processed 1 h after collection as described earlier.10
The following parameters of the thrombelastograph (TEGâ)
trace were analysed: reaction time (r), coagulation time (k),
maximum amplitude (MA), angle (a) and clot lysis 30
(Ly30) 30 min after reaching MA. Kidney function was
assessed using serum creatinine and cystatin c11 both
before the operation and at 24 h. In addition, in patients
undergoing hysterectomy creatinine clearance was meas-
ured from the end of surgery until 24 h. A set of standard
clinical laboratory tests, including haemoglobin, was per-
formed not earlier than 72 h before induction of anaesthesia
and at 24 h.
The primary outcome variable was platelet aggregation
stimulated with arachidonic acid. Calculations of the
necessary sample size were done according to our own
preliminary data and the work of Leese and colleagues.6 The
inclusion of 18 patients in each drug group was determined
to yield 90% power to detect a reduction of 40% in
Table 1 (A) Patient characteristics and surgical and anaesthesiological data in the intent-to-treat population (n=50). Data are mean (range) for age or mean
(SD). *Uneven distribution of the three types of breast surgery between the two drug groups (P=0.01). (B) Patient characteristics and surgical, and
anaesthesiological data for the subgroup (n=38) (excluding, abdominal hysterectomy, minor breast surgery and mastectomy patients). Data are mean (range)
for age or mean (SD). There were no signi®cant differences between the two drug and surgery groups
(A) Rofecoxib Diclofenac
Hysterectomy Breast surgery Hysterectomy Breast surgery
Number (n) 13 12 12 13
Vaginal/transabdominal hysterectomy 1/12 ± 2/10 ±
Lumpectomy/tumour and axilla dissection/mastectomy ± 5/7/0 ± 0/9/4*
ASA I/II/III 5/8/0 7/5/0 9/3/0 5/7/1
Age (yr) 53 (39±73) 48 (29±70) 49 (36±74) 53 (36±67)
Height (cm) 163 (7) 166 (6) 163 (7) 166 (4)
Weight (kg) 69 (11) 62 (9) 66 (10 65 (10)
Haemoglobin baseline (g litre±1) 130 (10) 126 (7) 123 (9) 134 (10)
Serum creatinine baseline (mmol litre±1) 77 (11) 81 (10) 80 (15) 80 (13)
Cystatin c baseline (mg litre±1) 1.01 (0.21) 0.99 (0.14) 1.00 (0.33) 1.03 (0.15)
Anaesthesia duration (min) 184 (61) 141 (50) 168 (74) 197 (53)
Operation duration (min) 136 (65) 93 (44) 124 (66) 134 (53)
Propofol, total dose (mg) 1432 (423) 1018 (56)3 1299 (514) 1331 (390)
Remifentanil, mean intraoperative rate (mg kg±1 min±1) 0.14 (0.09) 0.08 (0.07) 0.12 (0.13) 0.13 (0.06)
(B) Rofecoxib Diclofenac
Hysterectomy Breast surgery Hysterectomy Breast surgery
Number (n) 12 7 10 9
Vaginal hysterectomy 12 ± 10 ±
Tumor and axilla dissection ± 7 ± 9
ASA I/II/III 4/8/0 2/5/0 7/3/0 3/5/1
Age (yr) 55 (42±73) 55 (44±70) 50 (36±74) 56 (42±67)
Height (cm) 163 (7) 165 (6) 163 (6) 167 (4)
Weight (kg) 68 (11) 62 (10) 66 (10) 66 (11)
Haemoglobin baseline (g litre±1) 131 (10) 127 (8) 125 (8) 134 (11)
Serum creatinine baseline (mmol litre±1) 78 (11) 78 (7) 77 (15) 80 (15)
Cystatin-C baseline (mg litre±1) 1.02 (0.22) 1.02 (0.12) 0.99 (0.36) 1.07 (0.16)
Anaesthesia duration (min) 185 (63) 176 (28) 178 (78) 207 (58)
Operation duration (min) 138 (67) 121 (28) 132 (69) 144 (60)
Propofol, total dose (mg) 1442 (440) 1334 (494) 1319 (552) 1452 (394)
Remifentanil, mean intraoperative rate (mg kg±1 min±1) 0.15 (0.09) 0.12 (0.04) 0.13 (0.13) 0.14 (0.07)
Rofecoxib vs diclofenac in gynaecological surgery
525
reactivity of platelet aggregation after arachidonic acid,
taking into account a standard deviation of 25% and a two-
sided t-test with a signi®cance level of 0.05.
Secondary outcome variables were blood loss during
operation, haemoglobin loss, VAS for pain, nicomorphine
consumption, use of rescue anti-emetics, PONV ratings, and
decreases in the parameters of the function of the kidney.
Statistical analysis
The drug groups were compared for patients from both types
of surgery using two-way factorial ANOVA. When the
same variable was analysed at different time points,
Bonferroni correction was applied. Effect size is presented
as the mean difference with the 95% con®dence interval
(CI). Data were transformed where appropriate to an
approximate normal distribution. For transformed data, the
standardized effect size (mean difference divided by
standard deviation) with 95% CI is shown. For categorical
data, logistic regression was used. All tests were two-sided,
and P values less than 0.05 were considered statistically
signi®cant.
Results
Patients
Fifty patients, with a median age of 48 yr, were enrolled in
the study; all were followed until 24 h. In the hysterectomy
group the surgical technique was changed during the
procedure in three of the 25 patients because of technical
dif®culties with a transvaginal approach to hysterectomy via
laparotomy (two subjects in the diclofenac group, one
subject in the rofecoxib group). These three patients had
more pain 1 h after emergence and a greater need for
nicomorphine until 24 h than the rest of the group (unpaired
t-test, P<0.05). In the breast surgery group, three types of
operation were performed; removal of a benign lesion,
tumour resection with dissection of the axilla, and mastec-
tomy. Despite randomization, there was an unequal distri-
bution of these three types of surgery between the two drug
groups. While all four mastectomy patients were rando-
mized to the diclofenac group, all ®ve patients with benign
lesions and lumpectomy were randomized to the rofecoxib
group (Mann±Whitney test, P<0.01). In two patients, the
16 h study medication was not given because of nausea
(breast surgery, rofecoxib group) and vomiting (hysterec-
tomy, diclofenac group). Two further patients received a
rescue analgesic of propyphenazone 125 mg and dihy-
droergotamine 0.5 mg according to the study protocol at 20
h (hysterectomy, diclofenac group) and 18 h (breast surgery,
rofecoxib group) for headache during the night after
surgery.
In an intention-to-treat analysis, all 50 patients were
included in the evaluation. The results were then controlled
by analysing the subgroup (n=38) including the vaginal
hysterectomy (n=22) and tumour with axilla dissection
patients only (n=16).
The two drug and surgical groups (n=50) were compar-
able with respect to ASA physical status, age, weight,
height, baseline values of haemoglobin, markers of kidney
function, duration of anaesthesia and surgery, and dosages
of propofol and remifentanil (Table 1A). The same was true
for the subgroup (n=38) (Table 1B). Age was the only
variable in which the subgroup (n=38, median 50 yr, range
36±74 yr) differed from the excluded patients (n=12,
median 41 yr, range 30±52 yr) (t-test, P<0.01).
Platelet aggregation stimulated with arachidonic acid
showed a reduction of activity after diclofenac compared
with no change after rofecoxib (mean difference 12%, 95%
Fig 1 Platelet aggregation stimulated with arachidonic acid 2 mmol
litre±1, collagen 5 mmol litre±1 and ADP 5 mmol litre±1. Data are for all
patients (n=50), and show the measurement 4 h after the ®rst study drug
minus the value measured immediately before the ®rst dose of the study
drug. Values are mean and SD. Two-way factorial ANOVA. *P=0.02 vs
diclofenac.
Fig 2 Platelet aggregation stimulated with arachidonic acid 2 mmol
litre±1, collagen 5 mmol litre±1 and ADP 5 mmol litre±1. Data are for the
subgroup (n=38) and show the measurement 4 h after the ®rst study drug
minus the value measured immediately before the ®rst dose of the study
drug. Values are mean and SD. Two-way factorial ANOVA. *P=0.01 vs
diclofenac.
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CI 22±2, P=0.02) (Fig. 1). This result remained valid in the
subgroup (Fig. 2). The slight increase in aggregation activity
in the rofecoxib group from the predose to the postdose
measurement (from 47 (32) to 55 (32)%, difference 9
(37)%) was statistically not signi®cant (t-test, P=0.26). No
difference in activity was found after platelet aggregation
stimulated with collagen or ADP (all patients, Fig. 1;
subgroup, Fig. 2). There were no differences between the
two drug groups in thrombelastography and MDA values
(Table 2). There was an increased estimated blood loss (all
patients (n=50), standardized effect size 1.22 SD, 95% CI
0.65±1.78 SD, P<0.01; subgroup (n=38), standardized effect
size 0.87 SD, 95% CI 0.20±1.53 SD, P=0.01), and a greater
reduction in haemoglobin in the diclofenac compared with
the rofecoxib group (all patients (n=50), mean difference
±4 g litre±1, 95% CI ±7 to ±1, P<0.01; subgroup (n=38),
mean difference ±4 g litre±1, 95% CI ±7 to ±1, P=0.01).
Haemoglobin loss was also greater in the hysterectomy
group compared with the breast surgery patients (all patients
(n=50), mean difference ±4 g litre±1, 95% CI ±7 to ±2,
P<0.01; subgroup (n=38), mean difference ±4 g litre±1, 95%
CI ±7 to ±1, P=0.01). No differences were found for
clinically estimated coagulation (Table 3).
VAS for pain was greater at 1 and 8 h in the hysterectomy
than in the breast surgery group. However, when the
subgroup (n=38) was analysed pain readings were similar.
No difference in VAS for pain was found between
rofecoxib- and diclofenac-treated patients (Table 4).
Cumulated doses of nicomorphine were higher in the
hysterectomy than in the breast surgery patients for the
whole observation period (all patients (n=50), standardized
effect size 1.07 SD, 95% CI 0.50±1.63 SD, P<0.01; subgroup
(n=38), standardized effect size 0.88 SD, 95% CI 0.22±1.54
SD, P=0.01), but similar between the rofecoxib and
Table 2 Coagulation studies before and 4 h after the ®rst study medication. No signi®cant differences. Thrombelastography TEGâ: reaction time (r),
coagulation time (k), maximum amplitude (MA), angle (a), lysis at 30 min (Ly30). Malondialdehyde produced by the platelets after stimulation by
arachidonic acid
Rofecoxib Diclofenac
Predose Postdose Predose Postdose
All patients (n=50)
Number (n) 25 25
TEGâ r (mm) 9 (4) 8 (3) 8 (2) 7 (2)
TEGâ k (mm) 3 (3) 3 (1) 3 (1) 3 (1)
TEGâ MA (mm) 63 (6) 62 (6) 62 (5) 61 (5)
TEGâ a (°) 71 (9) 74 (5) 73 (4) 74 (4)
TEGâ Ly30 (%) 2 (1) 2 (1) 2 (1) 2 (1)
Malondialdehyde produced by platelets (mg litre±1) 3.5 (1.0) 3.1 (1.0) 3.5 (1.0) 3.0 (1.2)
Subgroup (n=38)
Number (n) 19 19
TEGâ r (mm) 9 (2) 8 (4) 8 (2) 7 (2)
TEGâ k (mm) 3 (1) 3 (1) 3 (1) 2 (1)
TEGâ MA (mm) 65 (5) 62 (6) 62 (5) 61 (5)
TEGâ a (°) 73 (3) 73 (6) 74 (3) 75 (3)
TEGâ Ly30 (%) 2 (1) 2 (1) 3 (1) 2 (1)
Malondialdehyde produced by platelets (mg litre±1) 3.7 (1.1) 3.3 (0.9) 3.6 (0.9) 3.1 (1.0)
Table 3 Blood loss and clinically estimated coagulation. Data are mean (SD). Two-way factorial ANOVA. Estimated coagulation is rated by the surgeon on a
®ve-point scale from no coagulation (1) to increased coagulation (5). Haemoglobin loss is haemoglobin concentration before operation minus the
concentration measured on the ®rst postoperative morning. *Rofecoxib vs diclofenac; +hysterectomy vs breast surgery
Rofecoxib Diclofenac *P vs
diclofenac
+P vs
breast surgery
All patients (n=50) Hysterectomy Breast surgery Hysterectomy Breast surgery
n 13 12 12 13
Intraoperative blood loss (ml) 173 (90)*+ 83 (54)* 279 (164)+ 235 (127) < 0.01 0.02
Clinically estimated coagulation (1±5) 2.9 (0.3) 3.0 (0.0) 2.6 (0.7) 2.8 (0.7) NS NS
Haemoglobin loss (g litre±1) 16 (9)*+ 6 (7)* 20 (11)+ 19 (7) <0.01 0.02
Subgroup (n=38) Vaginal
hysterectomy
Tumour and
axilla dissection
Vaginal
hysterectomy
Tumour and
axilla dissection
n 12 7 10 9
Intraoperative blood loss (ml) 179 (92)* 117 (33)* 295 (177) 212 (120) 0.01 NS
Clinically estimated coagulation (1±5) 2.9 (0.3) 3.0 (0.0) 2.6 (0.7) 2.9 (0.3) NS NS
Haemoglobin loss (g litre±1) 18 (8)*+ 6 (7)* 21 (11)+ 18 (6) 0.01 0.01
Rofecoxib vs diclofenac in gynaecological surgery
527
diclofenac groups (Table 5). When the dosages between the
individual assessment points were analysed, the breast
surgery patients requested less nicomorphine between 1 and
4 h and between 1 and 8 h compared with hysterectomy
patients. Between the 8 and 24 h assessments, all groups
requested similar dosages of nicomorphine (data not
shown). Analgesia over the whole study period was rated
4.1 (0.8) in the rofecoxib and 3.8 (0.8) in the diclofenac
group on the ®ve-item VRS (P=0.18). Further details are
given in Table 6A and B.
Heart rate and blood pressure measurements were similar
for all groups. PONV recordings were similar between the
drug groups (Table 6A and B). However, there was a reduced
requirement for rescue anti-emetic medication in the
rofecoxib group (all patients (n=50), standardized effect
size 0.72 SD, 95% CI 0.16±1.28 SD, P=0.01; subgroup
(n=38), standardized effect size 0.74 SD, 95% CI 0.08±1.40
SD, P=0.03). The greater satisfaction in the global evalu-
ation of PONV at 24 h in the rofecoxib group (P=0.03) (all
patients) was not maintained when the subgroup was
analysed (P=0.14).
One patient in the diclofenac group undergoing breast
surgery developed a wound haematoma which required
evacuation. No patient developed an increase in serum
creatinine of >9 mmol litre±1. No differences were found in
the course of serum creatinine or cystatin c between the two
drug groups (Table 6A and B). The same was true for
creatinine clearance (hysterectomy patients only). There
Table 4 Pain assessment: VAS 0±100 mm at the four assessment times. Data are mean (SD). *Hysterectomy vs breast surgery. P values <0.0125 are
signi®cant after Bonferroni correction
All patients (n=50) Hysterectomy Breast surgery *P
Rofecoxib Diclofenac Rofecoxib Diclofenac
n 13 12 12 13
1 h after surgery 45 (31)* 61 (27)* 29 (17) 38 (25) 0.009
4 h after surgery 26 (19)* 37 (20)* 19 (14) 19 (15) 0.011
8 h after study drug 29 (20)* 30 (22)* 11 (10) 19 (17) 0.008
24 h after study drug 18 (13) 21 (16) 16 (19) 15 (11) NS
Subgroup (n=38) Vaginal hysterectomy Tumour and axilla dissection
Rofecoxib Diclofenac Rofecoxib Diclofenac
n 12 10 7 9
1 h after surgery 44 (31) 54 (23) 32 (17) 35 (23) NS
4 h after surgery 25 (19) 36 (21) 17 (7) 20 (17) NS
8 h after study drug 28 (21) 29 (24) 14 (8) 20 (17) NS
24 h after study drug 20 (12) 23 (16) 7 (5) 19 (11) NS
Table 5 Cumulative doses of nicomorphine (mg) at the four assessment times. Data are mean (SD). Two-way factorial ANOVA. *Hysterectomy vs breast
surgery. P values <0.0125 are signi®cant after Bonferroni correction
All patients (n=50) Hysterectomy Breast surgery *P vs
breast surgery
P vs diclofenac
Rofecoxib Diclofenac Rofecoxib Diclofenac
n 13 12 12 13
1 h postoperative 12 (11)* 11 (4)* 4 (4) 8 (4) <0.001 NS
4 h postoperative 20 (14)* 19 (6)* 6 (5) 13 (6) <0.001 NS
8 h after study drug 22 (15)* 20 (7)* 6 (5) 14 (6) <0.001 NS
24 h after study drug 32 (31)* 29 (17)* 9 (7) 21 (14) 0.001 NS
Subgroup (n=38) Vaginal hysterectomy Tumour and axilla dissection
Rofecoxib Diclofenac Rofecoxib Diclofenac
n 12 10 7 9
1 h after surgery 10 (7)* 12 (4)* 5 (4) 9 (5) 0.012 NS
4 h postoperative 17 (10)* 19 (7)* 7 (5) 15 (6) 0.003 NS
8 h after study drug 19 (11)* 21 (8)* 8 (5) 15 (7) 0.002 NS
24 h after study drug 25 (15)* 29 (18)* 9 (6) 23 (14) 0.012 NS
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were no serious side-effects. However, three (12%) of the
diclofenac and one (4%) of the rofecoxib patients com-
plained of epigastric pain.
Discussion
This study compared the effects on platelet function,
bleeding parameters, safety, and analgesic ef®cacy of a
single preoperative oral dose of the COX-2-speci®c
inhibitor rofecoxib 50 mg vs three oral doses of the COX-
non-selective NSAID diclofenac sodium 50 mg. Rofecoxib
compromised platelet aggregation stimulated with arachi-
donic acid less than did diclofenac. The estimated surgical
blood loss was less and the decrease in haemoglobin
concentration until the postoperative morning was smaller
in the rofecoxib than in the diclofenac group. Ratings of
analgesia and the use of rescue opioids were similar in the
two drug groups. In addition, the use of anti-emetic
medication was reduced in the rofecoxib group.
We assessed the effect of the two study drugs on
coagulation by platelet aggregation stimulated with arachi-
donic acid, the primary endpoint of the study. This test is
sensitive to the inhibition of the COX-1 by NSAIDs.6 While
non-selective NSAIDs such as diclofenac inhibit both
COX-1 and COX-2 to a varying degree, COX-2-selective
drugs predominantly block the latter enzyme only.12 13
Although the study hypothesis (that rofecoxib possesses a
smaller inhibitory effect on COX-1 compared with
diclofenac) was con®rmed, the decrease in aggregation
activity in the diclofenac group was smaller than expected14
but was in accordance with the measurements of Van Heck
and colleagues.15 This might have been because the timing
Table 6A Side-effects in the intent-to-treat population (n=50). Data are n (%) or mean (SD). Two-way factorial ANOVA for continuous and logistic
regression for categorical data. P values are for rofecoxib vs diclofenac. `VRS global evaluation PONV' indicates a verbal rating scale for satisfaction with
PONV from 1 (poor) to 5 (excellent) until 8 and 24 h after the ®rst dose of the study drug. Ramsey scale31
Rofecoxib Diclofenac P
Number (n) 25 25
Difference (post±preop) in serum creatinine (mmol litre±1) ±8 (7) ±10 (7) NS
Difference (post±preop) in cystatin c (mg litre±1) ±0.09 (0.20) ±0.12 (0.28) NS
Creatinine clearance (ml min±1) (hysterectomy patients only) 104 (49) 110 (29) NS
Epigastric pain (n) 1 (4) 3 (12) NS
Anti-emetic doses administered per patient 0.5 (0.8)* 1.2 (1.1) 0.01
Nausea (n) 3 (12) 6 (24) NS
Vomiting (n) 2 (8) 6 (24) NS
VRS global evaluation analgesia until 8 h (1±5) 3.8 (0.9) 3.6 (0.8) NS
VRS global evaluation analgesia until 24 h (1±5) 4.1 (0.8) 3.8 (0.8) NS
VRS global evaluation PONV until 8 h (1±5) 3.9 (0.9) 3.6 (0.8) NS
VRS global evaluation PONV until 24 h (1±5) 4.0 (1.0)* 3.3 (0.9) 0.03
Wound haematoma (n) 0 (0) 1 (4) NS
Headache (n) 5 (20) 5 (20) NS
Sedation: Ramsey scale 2 sleepy (n) 14 (56) 15 (60) NS
Sedation: Ramsey scale 3 easy arousable (n) 4 (16) 3 (12) NS
Table 6B Side-effects (n=38) (excluding abdominal hysterectomy, minor breast surgery and mastectomy patients). Data are n (%) or mean (SD). Rofecoxib vs
diclofenac. Two-way factorial ANOVA for continuous and logistic regression for categorical data. P values are for rofecoxib vs diclofenac. `VRS global
evaluation PONV' indicates a verbal rating scale for satisfaction with PONV from 1 (poor) to 5 (excellent) until 8 and 24 h after the ®rst dose of the study
medicament. Ramsey scale31
Rofecoxib Diclofenac P
Number (n) 19 19
Epigastric pain (n) 1 (5) 2 (11) NS
Difference (post±preop) serum creatinine (mmol litre±1) ±9 (7) ±9 (7) NS
Difference (post±preop) cystatin c (mg litre±1) ±0.11 (0.22) ±0.10 (0.32) NS
Creatinine clearance (ml min±1) (hysterectomy patients only) 101 (50) 109 (31) NS
Anti-emetic doses administered per patient 0.5 (0.9)* 1.3 (1.2) 0.03
Nausea (n) 3 (16) 5 (26) NS
Vomiting (n) 2 (11) 5 (26) NS
VRS global evaluation analgesia until 8 h (1±5) 3.8 (1.0) 3.5 (0.8) NS
VRS global evaluation analgesia until 24 h (1±5) 4.1 (0.9) 3.8 (0.9) NS
VRS global evaluation PONV until 8 h (1±5) 3.8 (0.9) 3.7 (0.7) NS
VRS global evaluation PONV until 24 h (1±5) 3.9 (1.2) 3.3 (1.0) NS
Wound haematoma (n) 0 (0) 1 (5) NS
Headache (n) 4 (21) 5 (26) NS
Sedation: Ramsey scale 2 sleepy (n) 10 (53) 10 (53) NS
Sedation: Ramsey scale 3 easy arousable (n) 4 (21) 2 (11) NS
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of the coagulation study 4 h after the ®rst dose was different
from the expected time of the peak plasma concentrations of
the drug,16 17 as the ®rst doses of both study drugs were
given immediately before anaesthesia induction, and
absorption of the drugs might have been slowed by i.v.
opioids.18 A further reason might be that the full effect on
the inhibition of aggregation is reached only after several
doses of an NSAID.6 Surprisingly, the MDA content of
platelets was not different between the two study groups,
although MDA is very sensitive to COX-1 inhibition of
platelets.9 It is likely that this could also be due to the timing
of the drug intake and altered absorption. In addition, there
was no difference between the two drug groups with respect
to thrombelastograph analysis. However, this is not very
sensitive to the effects of NSAIDs.19
Concerns have been raised by Mukherjee and col-
leagues,20 who found an increased incidence of thrombotic
cardiovascular adverse events (TCAE) in the rofecoxib 50
mg daily group when reanalysing the VIGOR trial.7
However, in the VIGOR trial rofecoxib was compared
with naproxen 1000 mg daily, an NSAID with a strong
inhibitory effect on platelet COX-1.15 When rofecoxib was
compared with placebo or non-selective NSAIDs in >5000
patients, no difference in the incidence of TCAE was
found.21 No TCAE was recorded in our patients and the
small numerical rise in platelet aggregation stimulated with
arachidonic acid after rofecoxib (Fig. 1) is not statistically
signi®cant. Although no signs of hypercoagulability were
observed in this study, the study population was too small to
de®nitively exclude slight postoperative hypercoagulability.
Increased blood loss has been observed when preopera-
tive non-selective COX inhibitors have been compared with
placebo4 or paracetamol.22 Interestingly, in this study a
greater estimated intraoperative blood loss and increased
loss of haemoglobin until 24 h was also observed in the
conventional NSAID group. The reason for this may well be
the reduced production of the coagulation activator
thromboxane B2, which is biosynthesized by COX-1.
23
The dose of rofecoxib used was based on previous
experience in the perioperative setting.24±26 Because
rofecoxib has a terminal half-life of 17 h,16 a single oral
dose can be expected to be active for almost 24 h. The
terminal half-life of diclofenac is 2 h and this drug must be
given 8-hourly if it is to stay effective. It has been used
widely in similar doses in the surgical setting.1 27 28 Thus,
our main questions were: (i) is rofecoxib as effective as
diclofenac, and (ii) does its effect fade after 8 h, after which
the diclofenac group gets additional drug doses? The
cumulative consumption of the rescue analgesic nicomor-
phine was lower in the breast surgery group than in the
hysterectomy group throughout the whole study period and
there was a trend for a lower consumption of nicomorphine
in the rofecoxib group than in the diclofenac group. In
addition, there was no increased need for rescue analgesics
in the rofecoxib group in the period from 8 until 24 h. In this
period the patients in the diclofenac group received two
additional doses of the respective NSAID while the
rofecoxib group received two placebos only. However,
satisfaction with pain treatment and readings of pain
assessment were not different between the two groups.
Recent work has clari®ed some questions regarding the
renal effects of selective COX-2 inhibitors. Prostacyclin,
synthesized in the kidney by COX-2, seems to play an
important role in the control of sodium reabsorption. When
prostacylin is reduced due to the inhibition of COX-2 by
NSAIDs or selective COX-2 inhibitors, this may lead to
oedema, hypertension and a reduction in glomerular ®ltra-
tion rate,29 and the incidence of renal failure provoked by
COX-2 inhibitors seems to be equal to that associated with
conventional NSAIDs.30 However, in our well-hydrated
patients, who received approximately 2.5 litres of Ringer's
lactate per day, serum markers of glomerular ®ltration fell
between the pre- and postoperative values, and in the
hysterectomy patients measured serum creatinine ®ltration
rate remained in the higher normal range even when
normalized to 1.73 m2 of body surface (106 ml min±1
1.73 m±2). This was true for both drug groups.
Besides analgesia, PONV represents an important deter-
minant of perioperative patient satisfaction. Although there
was no difference in the number of episodes of nausea or
vomiting, the use of anti-emetics was smaller in the
rofecoxib group. This was also true for the subgroup but
the greater satisfaction in the rofecoxib group with respect
to PONV at 24 h in all patients was not maintained in the
subgroup.
Regarding gastrointestinal side-effects, the population
studied were a relatively healthy group, because a history of
upper gastrointestinal pathology or past problems with oral
NSAIDs constituted a criterion for exclusion from the study.
Despite this, one subject in the rofecoxib group and three
patients in the diclofenac group complained of upper
abdominal discomfort. A postoperative haemorrhage re-
quired evacuation in one patient in the diclofenac group.
There were no other severe side-effects.
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